NCT00384787View on ClinicalTrials.gov

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

December 31, 2012

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC-HIVDNA009-00-VP

HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2

BIOLOGICAL

VRC-HIVADV014-00-VP

Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6

Trial Locations (7)

1

ACSA CRS, Iquitos

10003

NY Blood Ctr./Union Square CRS, New York

10455

NY Blood Ctr./Bronx CRS, The Bronx

35294

Alabama Vaccine CRS, Birmingham

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

10032-3732

Columbia P&S CRS, New York

98109-1024

Seattle Vaccine and Prevention CRS, Seattle

All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00384787 - Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults | Biotech Hunter | Biotech Hunter